Ziprasidone decreases cortisol excretion in healthy subjects

British Journal of Clinical Pharmacology

Volumn 60, Issue 3, 2005, Pages 330-336

  Meier, Andreas ^a   Neumann, Anna Catharina ^a   Jordan, Wolfgang ^a   Huether, Gerald ^a   Rodenbeck, Andrea ^a   Rüther, Eckart ^a   Cohrs, Stefan ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Department of Psychiatry and Psychotherapy ^*  (Germany)

Author keywords

Antipsychotics; Cortisol; HPA axis; Urinary excretion; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HYDROCORTISONE; PLACEBO; ZIPRASIDONE;

ADULT; ARTICLE; AUDITORY STIMULATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SLEEP; STRESS; URINARY EXCRETION;

ACOUSTIC STIMULATION; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; HUMANS; HYDROCORTISONE; MALE; PIPERAZINES; STRESS; THIAZOLES;

EID: 24044505692     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02431.x     Document Type: Article

References (40)

1. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Brier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-88.
2. Calabrese JR, Macfadden W, McCoy R, Minkwitz M, Wilson E, Mullen J. Double-blind, placebo-controlled study of quetiapine in bipolar depression. In American Psychiatric Association 157th Annual Meeting, 2004. New York, USA: American Psychiatric Association 2004, p284, NR756.
3. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004; 65: 217-21.
4. Rothschild AJ. The hypothalamic-pituitary-adrenal axis and psychiatric illness. In Wolkowitz, OM, Rothschild, AJ, eds. Psychoneuroendocrinology. The Scientific Basis of Clinical Practice. Arlington: American Psychiatrist Publishing, Inc. 2003, p. 139-64.
5. Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: does cortisol play a role? Biol Psychiatry 2004; 55: 1-9.
6. Slattery DA, Hudson AL, Nutt DJ. Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol 2004; 18: 1-21.
7. Lammers CH, Garcia Borreguero D, Schmider J, Gotthardt U, Dettling M, Holsboer F, Heuser IJ. Combined dexamethasone/ corticotropin-releasing hormone test in patients with schizophrenia and in normal controls, II. Biol Psychiatry 1995; 38: 803-7.
8. Jakovljevic M, Muck Seler D, Pivac N, Crncevic Z. Platelet 5-HT and plasma cortisol concentrations after dexamethasone suppression test in patients with different time course of schizophrenia. Neuropsychobiology 1998; 37: 142-5.
9. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284-9.
10. Tandon R, Silk KR, Greden JF, Goodson J, Hariharan M, Meador-Woodruff JH, Kronfol Z. Positive and negative symptoms in schizophrenia and the Dexamethasone Suppression Test. Biol Psychiatry 1989; 25: 788-92.
11. Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T. Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr Res 2002; 58: 69-74.
12. Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry 2000; 48: 1121-32.
13. Tandon R, DeQuardo JR, Taylor SF, McGrath M, Jibson M, Eiser A, Goldman M. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 2000; 45: 191-201.
14. Meltzer HY. Clinical studies on the mechanism of action of clozapine. The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Bed) 1989; 99(Suppl ): S18-27.
15. Hatzimanolis J, Lykouras L, Markianos M, Oulis P. Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 1077-85.
16. Markianos M, Hatzimanolis J, Lykouras L. Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur Neuropsychopharmacol 1999; 9: 533-6.
17. Scheepers FE, Gespen de Wied CC, Kahn RS. The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia. J Clin Psychopharmacol 2001; 21: 575-82.
18. Cohrs S, Pohlmann K, Guan Z, Jordan W, Meier A, Huether G, Rüther E, Rodenbeck A. Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects. Psychopharmacology (Berl) 2004; 174: 414-20.
19. Wetzel H, Wiesner J, Hiemke C, Benkert O. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers. J Psychiatr Res 1994; 28: 461-73.
20. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA. 3rd Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101-13.
21. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003; 64(Suppl 19): 6-12.
22. Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999; 368: 277-83.
23. Laakmann G, Hinz A, Voderholzer U, Daffner C, Muller OA, Neuhauser H, Neulinger E, Wittman M. The influence of psychotropic drugs and releasing hormones on anterior pituitary hormone secretion in healthy subjects and depressed patients. Pharmacopsychiatry 1990; 23: 18-26.
24. Seibyl JP, Krystal JH, Price LH, Woods SW, D'Amico C, Heninger GR, Charney DS. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res 1991; 38: 227-36.
25. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS. 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 2001; 21: 3572-9.
26. Contesse V, Lefebvre H, Lenglet S, Kuhn JM, Delarue C, Vaudry H. Role of 5-HT in the regulation of the brain-pituitary-adrenal axis: effects of 5-HT on adrenocortical cells. Can J Physiol Pharmacol 2000; 78: 967-83.
27. Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A, Rüther E. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl) 2004; 174: 421-9.
28. Hajak G, Rodenbeck A, Ehrenthal HD, Leonard S, Wedekind D, Sengos G, Zhou D, Huether G. No evidence for a physiological coupling between melatonin and glucocorticoids. Psychopharmacol Berl 1997; 133: 313-22.
29. Owen RR Jr, Gutierrez Esteinou R, Hsiao J, Hadd K, Benkelfat C, Lawlor BA, Murphy DL, Pickar D. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 1993; 50: 636-44.
30. Kahn RS, Davidson M, Siever LJ, Sevy S, Davis KL. Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine. Biol Psychiatry 1994; 35: 909-12.
31. Dinan TG. Stress and the genesis of diabetes mellitus in schizophrenia. Br J Psychiatry Suppl 2004; 47: S72-5.
32. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337-45.
33. Kahn RS, Siever L, Davidson M, Greenwald C, Moore C. Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology (Berl) 1993; 112 (1 Suppl): S90-4.
34. Lee MA, Nash JF, Barnes M, Meltzer HY. Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans. Psychopharmacology (Berl) 1991; 103: 258-64.
35. Facchinetti F, Martignoni E, Nappi G, Marini S, Petraglia F, Sandrini G, Genazzani AR. Ritanserin, a serotonin-S2 receptor antagonist, does not prevent 5-hydroxytryptophan-induced beta-EP, beta-LPH and cortisol secretion. Norm Res 1987; 27: 42-6.
36. Tepavcevic D, Giljevic Z, Korsic M, Halimi S, Suchanek E, Jelic T, Aganovic I, Kozic B, Plavsic V. Effects of ritanserin, a novel serotonin-S2 receptor antagonist, on the secretion of pituitary hormones in normal humans. J Endocrinol Invest 1994; 17: 1-5.
37. Barbieri C, Sala M, Bigatti G, Rauhe WG, Guffanti A, Diena A, Scorza D, Bevilacqua M, Norbiato G. Serotonergic regulation of cortisol secretion in dogs. Endocrinology 1984; 115: 748-51.
38. Hemrick Luecke SK, Evans DC. Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT) (2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT (2A) receptor mediation of the HPA axis. Neuropharmacology 2002; 42: 162-9.
39. Zoccali C, Zabludowski JR, Isles CG, Murray GD, Inglis GC, Robertson JI, Fraser R, Ball SG. The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man. Br J Clin Pharmacol 1983; 16: 305-11.
40. Laakmann G, Wittmann M, Schoen HW, Zygan K, Weiss A, Meissner R, Mueller OA, Stalla GK. Effects of receptor blockers (methysergide, propranolol, phentolamine, yohimbine and prazosin) on desimipramine-induced pituitary hormone stimulation in humans - III. Hypothalamo-pituitary-adrenocortical axis. Psychoneuroendocrinology 1986; 11: 475-89.